Title | Type | SJR | H index | Total Docs. (2023) | Total Docs. (3years) | Total Refs. (2023) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2023) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
143 | Biologicals | journal | 0.452 Q3 | 66 | 42 | 154 | 1276 | 287 | 152 | 1.49 | 30.38 | |
142 | Behavioural Pharmacology | journal | 0.455 Q3 | 87 | 49 | 197 | 2397 | 323 | 193 | 1.67 | 48.92 | |
141 | Reading Teacher | journal | 0.455 Q3 | 60 | 95 | 264 | 3409 | 393 | 228 | 1.33 | 35.88 | |
140 | International Journal of Toxicology | journal | 0.467 Q3 | 71 | 91 | 171 | 2897 | 335 | 156 | 1.30 | 31.84 | |
139 | Drug Development and Industrial Pharmacy | journal | 0.475 Q2 | 100 | 71 | 454 | 3365 | 1412 | 454 | 2.31 | 47.39 | |
138 | Anti-Cancer Drugs | journal | 0.476 Q3 | 102 | 143 | 526 | 4507 | 1045 | 525 | 1.89 | 31.52 | |
137 | Pharmaceutical Development and Technology | journal | 0.476 Q2 | 70 | 86 | 328 | 5162 | 1012 | 324 | 2.57 | 60.02 | |
136 | Steroids | journal | 0.476 Q3 | 114 | 110 | 346 | 6032 | 899 | 342 | 2.28 | 54.84 | |
135 | Current Cardiovascular Risk Reports | journal | 0.491 Q3 | 34 | 21 | 72 | 1537 | 119 | 72 | 1.94 | 73.19 | |
134 | Current Therapeutic Research | journal | 0.495 Q3 | 46 | 37 | 110 | 1384 | 214 | 108 | 1.60 | 37.41 | |
133 | Dose-Response | journal | 0.507 Q3 | 48 | 53 | 442 | 2484 | 1017 | 393 | 2.08 | 46.87 | |
132 | Value in Health Regional Issues | journal | 0.525 Q1 | 28 | 89 | 268 | 3569 | 416 | 254 | 1.48 | 40.10 | |
131 | Critical Reviews in Therapeutic Drug Carrier Systems | journal | 0.536 Q2 | 82 | 17 | 53 | 3290 | 172 | 53 | 2.83 | 193.53 | |
130 | Drug and Chemical Toxicology | journal | 0.542 Q3 | 54 | 166 | 463 | 8999 | 1288 | 463 | 2.73 | 54.21 | |
129 | American Journal of Therapeutics | journal | 0.544 Q3 | 69 | 133 | 510 | 2694 | 449 | 146 | 0.81 | 20.26 | |
128 | American Journal of Health-System Pharmacy | journal | 0.557 Q3 | 107 | 308 | 1159 | 2543 | 1504 | 937 | 1.09 | 8.26 | |
127 | Helvetica Chimica Acta | journal | 0.557 Q2 | 87 | 119 | 189 | 5904 | 330 | 184 | 1.63 | 49.61 | |
126 | Pharmacogenetics and Genomics | journal | 0.563 Q1 | 152 | 25 | 97 | 907 | 208 | 95 | 1.94 | 36.28 | |
125 | Journal of Aerosol Medicine and Pulmonary Drug Delivery | journal | 0.571 Q2 | 81 | 36 | 120 | 1613 | 374 | 110 | 1.73 | 44.81 | |
124 | Toxicologic Pathology | journal | 0.575 Q3 | 124 | 35 | 262 | 1668 | 524 | 255 | 1.79 | 47.66 | |
123 | International Nano Letters | journal | 0.586 Q2 | 26 | 20 | 90 | 1419 | 441 | 90 | 5.05 | 70.95 | |
122 | Therapeutic Drug Monitoring | journal | 0.591 Q2 | 102 | 116 | 328 | 4136 | 846 | 295 | 2.68 | 35.66 | |
121 | Journal of the American Pharmacists Association : JAPhA | journal | 0.593 Q2 | 73 | 266 | 803 | 7419 | 1409 | 658 | 1.83 | 27.89 | |
120 | Microbial Drug Resistance | journal | 0.596 Q2 | 78 | 74 | 523 | 2996 | 1273 | 508 | 2.40 | 40.49 | |
119 | Journal of Ocular Pharmacology and Therapeutics | journal | 0.599 Q2 | 72 | 89 | 262 | 3820 | 591 | 235 | 1.78 | 42.92 | |
118 | Cancer Biotherapy and Radiopharmaceuticals | journal | 0.607 Q2 | 68 | 91 | 285 | 3180 | 871 | 281 | 2.79 | 34.95 | |
117 | Biotechnology and Applied Biochemistry | journal | 0.610 Q2 | 81 | 185 | 488 | 10036 | 1787 | 482 | 3.72 | 54.25 | |
116 | Bulletin of Mathematical Biology | journal | 0.610 Q2 | 97 | 122 | 406 | 6141 | 892 | 403 | 2.14 | 50.34 | |
115 | Journal of Cardiovascular Pharmacology | journal | 0.610 Q2 | 109 | 113 | 574 | 4825 | 1358 | 538 | 2.24 | 42.70 | |
114 | Topics in antiviral medicine | journal | 0.614 Q2 | 46 | 18 | 36 | 403 | 63 | 36 | 1.89 | 22.39 | |
113 | Alcohol | journal | 0.621 Q2 | 88 | 70 | 227 | 4212 | 508 | 223 | 2.21 | 60.17 | |
112 | Human and Experimental Toxicology | journal | 0.621 Q2 | 91 | 97 | 542 | 4599 | 1623 | 536 | 2.79 | 47.41 | |
111 | Clinical Pharmacology in Drug Development | journal | 0.626 Q2 | 35 | 140 | 398 | 3021 | 753 | 385 | 1.86 | 21.58 | |
110 | Contemporary Clinical Trials Communications | journal | 0.636 Q2 | 26 | 176 | 511 | 7402 | 849 | 507 | 1.52 | 42.06 | |
109 | Therapeutic Innovation and Regulatory Science | journal | 0.637 Q1 | 51 | 129 | 419 | 3922 | 814 | 374 | 2.24 | 30.40 | |
108 | Artificial Cells, Nanomedicine and Biotechnology | journal | 0.646 Q2 | 86 | 53 | 270 | 3059 | 1067 | 257 | 3.83 | 57.72 | |
107 | IEEE Transactions on Nanobioscience | journal | 0.659 Q2 | 73 | 119 | 198 | 4764 | 744 | 194 | 4.10 | 40.03 | |
106 | Neuropsychopharmacology Reports | journal | 0.660 Q2 | 22 | 105 | 201 | 3867 | 480 | 199 | 2.40 | 36.83 | |
105 | Bulletin of Environmental Contamination and Toxicology | journal | 0.665 Q2 | 86 | 184 | 887 | 7061 | 2735 | 871 | 3.10 | 38.38 | |
104 | Current Protocols in Pharmacology | journal | 0.670 Q2 | 39 | 0 | 11 | 0 | 30 | 11 | 0.00 | 0.00 | |
103 | Cancer Nanotechnology | journal | 0.671 Q2 | 36 | 83 | 90 | 4754 | 399 | 89 | 4.21 | 57.28 | |
102 | Journal of Texture Studies | journal | 0.671 Q2 | 66 | 80 | 229 | 3881 | 785 | 222 | 2.95 | 48.51 | |
101 | Prostaglandins and Other Lipid Mediators | journal | 0.671 Q2 | 86 | 56 | 156 | 3893 | 431 | 151 | 2.43 | 69.52 | |
100 | Drug Development Research | journal | 0.672 Q2 | 67 | 112 | 371 | 6813 | 1390 | 345 | 3.72 | 60.83 | |
99 | Journal of Gene Medicine | journal | 0.679 Q2 | 100 | 101 | 265 | 4551 | 840 | 261 | 3.50 | 45.06 | |
98 | Profiles of Drug Substances, Excipients and Related Methodology | journal | 0.688 Q2 | 29 | 7 | 21 | 562 | 185 | 7 | 10.64 | 80.29 | |
97 | Journal of Pharmacokinetics and Pharmacodynamics | journal | 0.694 Q2 | 70 | 55 | 154 | 2186 | 403 | 144 | 2.25 | 39.75 | |
96 | PPAR Research | journal | 0.698 Q2 | 59 | 15 | 69 | 877 | 199 | 69 | 3.25 | 58.47 | |
95 | Journal of Biochemical and Molecular Toxicology | journal | 0.700 Q2 | 69 | 278 | 745 | 14722 | 2619 | 744 | 3.63 | 52.96 | |
94 | Toxicology Reports | journal | 0.700 Q2 | 64 | 138 | 638 | 7649 | 2558 | 634 | 3.74 | 55.43 |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®